These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9586668)

  • 1. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer.
    Powles TJ; McCloskey E; Paterson AH; Ashley S; Tidy VA; Nevantaus A; Rosenqvist K; Kanis J
    J Natl Cancer Inst; 1998 May; 90(9):704-8. PubMed ID: 9586668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
    Välimäki MJ; Laitinen K; Patronen A; Puolijoki H; Seppänen J; Pylkkänen L; Aranko SM; Sairanen S; Blåfield H; Rekiaro M; Väisänen K; Kormano M; Mäkinen L; Salmi J; Ala-Kaila K; Perttilä J; Vesterinen K; Koivunoro K;
    Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.
    Saarto T; Blomqvist C; Välimäki M; Mäkelä P; Sarna S; Elomaa I
    J Clin Oncol; 1997 Apr; 15(4):1341-7. PubMed ID: 9193325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer.
    McCloskey E; Paterson A; Kanis J; Tähtelä R; Powles T
    Eur J Cancer; 2010 Feb; 46(3):558-65. PubMed ID: 20031392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment.
    Vehmanen L; Saarto T; Elomaa I; Mäkelä P; Välimäki M; Blomqvist C
    Eur J Cancer; 2001 Dec; 37(18):2373-8. PubMed ID: 11720830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer.
    Rizzoli R; Forni M; Schaad MA; Slosman DO; Sappino AP; Garcia J; Bonjour JP
    Bone; 1996 Jun; 18(6):531-7. PubMed ID: 8805993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer.
    Saarto T; Vehmanen L; Elomaa I; Välimäki M; Mäkelä P; Blomqvist C
    Br J Cancer; 2001 Apr; 84(8):1047-51. PubMed ID: 11308252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients.
    Herrala J; Puolijoki H; Liippo K; Raitio M; Impivaara O; Tala E; Nieminen MM
    Bone; 1998 May; 22(5):577-82. PubMed ID: 9600795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.
    Saarto T; Blomqvist C; Välimäki M; Mäkelä P; Sarna S; Elomaa I
    Br J Cancer; 1997; 75(4):602-5. PubMed ID: 9052418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cyclical intravenous clodronate therapy on bone mineral density and markers of bone turnover in patients receiving home parenteral nutrition.
    Haderslev KV; Tjellesen L; Sorensen HA; Staun M
    Am J Clin Nutr; 2002 Aug; 76(2):482-8. PubMed ID: 12145026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026].
    Powles T; Paterson A; McCloskey E; Schein P; Scheffler B; Tidy A; Ashley S; Smith I; Ottestad L; Kanis J
    Breast Cancer Res; 2006; 8(2):R13. PubMed ID: 16542503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer.
    Powles T; Paterson S; Kanis JA; McCloskey E; Ashley S; Tidy A; Rosenqvist K; Smith I; Ottestad L; Legault S; Pajunen M; Nevantaus A; Männistö E; Suovuori A; Atula S; Nevalainen J; Pylkkänen L
    J Clin Oncol; 2002 Aug; 20(15):3219-24. PubMed ID: 12149294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
    McCloskey E; Selby P; Davies M; Robinson J; Francis RM; Adams J; Kayan K; Beneton M; Jalava T; Pylkkänen L; Kenraali J; Aropuu S; Kanis JA
    J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease.
    Abitbol V; Briot K; Roux C; Roy C; Seksik P; Charachon A; Bouhnik Y; Coffin B; Allez M; Lamarque D; Chaussade S
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1184-9. PubMed ID: 17683996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
    Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
    Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.
    Paterson AH; Anderson SJ; Lembersky BC; Fehrenbacher L; Falkson CI; King KM; Weir LM; Brufsky AM; Dakhil S; Lad T; Baez-Diaz L; Gralow JR; Robidoux A; Perez EA; Zheng P; Geyer CE; Swain SM; Costantino JP; Mamounas EP; Wolmark N
    Lancet Oncol; 2012 Jul; 13(7):734-42. PubMed ID: 22704583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness of cyclic and continuous oral clodronate therapy on bone density and markers in osteopenic postmenopausal women.
    Tsai KS; Hsu SH; Yang RS; Cheng WC; Chieng PU
    Calcif Tissue Int; 1999 May; 64(5):384-8. PubMed ID: 10203414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended safety profile of oral clodronate after long-term use in primary breast cancer patients.
    Atula S; Powles T; Paterson A; McCloskey E; Nevalainen J; Kanis J
    Drug Saf; 2003; 26(9):661-71. PubMed ID: 12814333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clodronate increases mineralization of callus after Colles' fracture: a randomized, double-blind, placebo-controlled, prospective trial in 32 patients.
    Adolphson P; Abbaszadegan H; Bodén H; Salemyr M; Henriques T
    Acta Orthop Scand; 2000 Apr; 71(2):195-200. PubMed ID: 10852328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.